Navidea Biopharmaceuticals (NYSE:NAVB) Research Coverage Started at StockNews.com
by Danessa Lincoln · The Markets DailyStockNews.com assumed coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a report released on Friday. The firm issued a sell rating on the stock.
Navidea Biopharmaceuticals Price Performance
NAVB stock opened at $0.00 on Friday. The stock has a market capitalization of $100,084.00, a PE ratio of -0.02 and a beta of 1.47. Navidea Biopharmaceuticals has a 1 year low of $0.00 and a 1 year high of $0.11.
About Navidea Biopharmaceuticals
Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases.
Featured Stories
- Five stocks we like better than Navidea Biopharmaceuticals
- Which Wall Street Analysts are the Most Accurate?
- 3 Stocks That Could Rise on European Bank Interest Rate Cuts
- Options Trading – Understanding Strike Price
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- MarketBeat Week in Review – 9/16 – 9/20